# Madrigal Pharmaceuticals Inc. (MDGL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $541.08, market value $12.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Madrigal Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 1.36**. A PEG of 1.36 is in the range usually read as fairly priced for its growth.
- **Price / sales: 9.7×**. Each dollar of revenue is priced at 9.7×.
- **Price / book: 23.9×**. The shares trade at 23.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.7%** (5-yr avg -6.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -25.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -30.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -47.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -34.3%**. Return on all capital, debt included, is -34.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -25.8%**. Each dollar of assets produces -25.8% of profit.

## Growth
- **Revenue growth (1 yr): 432.1%**. Revenue grew 432.1% over the last year.
- **EPS growth (1 yr): 41.3%**. Earnings per share rose 41.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.56**. Debt is 0.56 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Madrigal Pharmaceuticals Inc. holds more cash than debt.
- **Altman Z-score: 12.06**. A Z-score of 12.06 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Madrigal Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 25.5%** (YTD -7.1%, 3-mo 11.1%). The shares are up 25.5% over twelve months including dividends.
- **From 52-week high: -12.0%** (37.5% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.35** (volatility 44%). Beta of 0.35 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDGL · Page: https://foliofundamentals.com/stocks/mdgl

Not investment advice.